| SEC

8-K Form - Current report, items 5.02 and 9.01 - Pharma-Bio Serv, Inc. (0001304161) (Filer)

8-K1pbsv_8k.htmCURRENT REPORTBlueprint
 

UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
WASHINGTON,D.C. 20549
 
FORM8-K
 
CURRENTREPORT PURSUANT
TOSECTION 13 or 15(d) OF THE
SECURITIESEXCHANGE ACT OF 1934
 
Date ofreport (Date of earliest event reported): October 7,2019
 
Pharma-BioServ, Inc.
(ExactName of Registrant as Specified in Its Charter)
 
Delaware
(Stateor Other Jurisdiction of Incorporation)
 
0-50956
20-0653570
(CommissionFile Number)
(I.R.S.Employer Identification No.)
 
6 Road696, Dorado, Puerto Rico
00646
(Addressof Principal Executive Offices)
(ZipCode)
 
(787)278-2709
(Registrant’sTelephone Number, Including Area Code)
 
(FormerName or Former Address, if Changed Since Last Report)
 
Checkthe appropriate box below if the Form 8-K filing is intended tosimultaneously satisfy the filing obligation of the registrantunder any of the following provisions (see General Instruction A.2.below):
 
☐Written communications pursuant to Rule 425 under the SecuritiesAct (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17 CFR 240.14a-12)
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under theExchange Act (17 CFR 240.14d-2(b))
 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under theExchange Act (17 CFR 240.13e-4(c))
 
Securitiesregistered pursuant to Section 12(b) of the Act: None
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
 
 
 
 
 
 
Indicateby check mark whether the registrant is an emerging growth companyas defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b2 of the Securities Exchange Act of 1934(17 CFR §240.12b2).
 
Emerging growthcompany
 
If anemerging growth company, indicate by check mark if the registranthas elected not to use the extended transition period for complyingwith any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act.
 


 
 
Item 5.02.       Departure ofDirectors or Certain Officers; Election of Directors; Appointmentof Certain Officers; Compensatory Arrangements of CertainOfficers.
 
OnOctober 7, 2019, Pharma-Bio Serv, Inc. (the “Company”)amended the Employment Agreement, of Pedro J. Lasanta, ChiefFinancial Officer of the Company, dated November 5, 2007, asamended (the "Amendment").  The Amendment modifies Mr.Lasanta's annual salary from $160,000 to $175,000 as of October 7,2019.
 
Acopy of the Amendment is attached as Exhibit 10.1 to this reportand is incorporated herein by this reference.
 
Item 9.01.       Financial Statementsand Exhibits.
 
(d)           Exhibits
 
Exhibit No.
 
Description
 
 
 
 
EmploymentAgreement Amendment, dated October 7, 2019, by and between theCompany and Pedro J. Lasanta.
 
 
 
 
 

 
 
SIGNATURES
 
Pursuantto the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalfby the undersigned hereunto duly authorized.
 
 
PHARMA-BIO SERV,INC.
 
 
 
 
 
Date:October 11, 2019
By:  
/s/ VictorSanchez  
 
 
 
VictorSanchez
 
 
 
Chief ExecutiveOfficer and President Europe Operations